Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumors-Reference-Cited by-同舟云学术

Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumors

Published:2021-10-06 Issue: Volume: Page:
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Heath Elisabeth I.^ORCID,Weise Amy,Vaishampayan Ulka,Danforth Dailan,Ungerleider Richard S.,Urata Yasuo

Funder

oncolys

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10637-021-01180-9.pdf

Reference10 articles.

1. Hrabeta J, Stiborova M, Adam V, Kizek R, Eckschlager T (2014) Histone deacetylase inhibitors in cancer therapy. A review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 158(2): 161–169. https://doi.org/10.5507/bp.2013.085

2. Kim HJ, Bae SC (2011) Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 3(2):166–179

3. Marks PA, Richon VM, Miller T, Kelly WK (2004) Histone deacetylase inhibitors. Adv Cancer Res 91: 137–168. https://doi.org/10.1016/S0065-230X(04)91004-4

4. Roth SY,Allis CD (1996) Histone acetylation and chromatin assembly: a single escort, multiple dances? Cell 87(1): 5–8. https://doi.org/10.1016/s0092-8674(00)81316-1

5. Spange S, Wagner T, Heinzel T, Kramer OH (2009) Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 41(1): 185–198. https://doi.org/10.1016/j.biocel.2008.08.027

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-Tumor Strategies by Harnessing the Phagocytosis of Macrophages;Cancers;2023-05-11

2. The mechanism of sodium butyrate on the growth of mouse B16 melanoma cells by inhibiting the differentiation of M2-type macrophages and down-regulating the expressions of VEGF and TGF-β;Biotechnology and Genetic Engineering Reviews;2023-04-17

3. Marine Organisms as a Prolific Source of Bioactive Depsipeptides;Marine Drugs;2023-02-11

4. Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies;npj Precision Oncology;2022-10-23